Pathway activity profiling can predict neoadjuvant endocrine therapy response in HR+ HER2- postmenopausal early stage breast cancer

Abstract Aim To improve patient selection for neoadjuvant endocrine therapy (NET), signal transduction pathway profiles of estrogen receptor (ER)-, androgen receptor (AR), were studied and compared to standard immunohistochemistry (IHC) in postmenopausal patients with HR+ (IHC ER ≥ 50%, progesterone...

ver descrição completa

Detalhes bibliográficos

Principais autores:	N. de Gruil, A. F. de Groot, Y. Wesseling-Rozendaal, D. Keizer, C.S. Koekenbier, S. Vermeer, D. Cohen, J. B. Heijns, C. M. P. W. Mandigers, A. J. van de Wouw, M. Cloos-van Balen, J. A. Ropela, H. M. Oosterkamp, M. L. van Bekkum, D. Houtsma, E. den Biezen, G. J. Liefers, S. C. Linn, J. R. Kroep
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2026-02-01
coleção:	Breast Cancer Research
Assuntos:	Postmenopausal Breast cancer HER2-negative Estrogen receptor Pathway Neoadjuvant endocrine therapy
Acesso em linha:	https://doi.org/10.1186/s13058-026-02245-4
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!